Viatris Inc. reported a loss of $279.2 million, or 23 cents per share, for the second quarter as the Cecil-based company continued its restructuring following its formation late last year through the merger of Mylan and Upjohn.
The loss compared to a profit of $39.4 million, or 8 cents a share, in the second quarter last year when Mylan was a standalone company.
Revenue for the second quarter was $4.58 billion vs. Mylan’s $2.73 billion a year earlier.
The pharmaceuticals giant reported adjusted earnings before interest, taxes, depreciation and amortization of $1.68 billion — a measure of profitability on operations before special charges.
“We delivered another quarter of strong results,” Viatris CEO Michael Goettler said in a statement Monday.
“We have strong momentum going into the second half of the year,” he told analysts in a morning conference call.
Read More
The company is on track to reach $500 million in cost savings this year and at least $1 billion by 2023, top executives said.
Part of the company’s restructuring plan included shutting down Mylan’s flagship generic drug plant in Morgantown, W.Va., on July 31, eliminating roughly 1,500 jobs.
The company said it paid down $1.15 billion in debt during the first half of the year and was on track to pay $6.5 billion through 2023.
Stronger-than-expected revenue for the second quarter led Viatris to raise its full-year revenue guidance to a range of $17.5 billion to $17.9 billion, up from a range of $17.2 billion to $17.8 billion.
Viatris shares rose 48 cents, or 3.4%, to $14.73 in early afternoon trading. The stock is down about 20% so far this year.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.